Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide Phase 1 MAD in Japanese T2DM
NCT04823208Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Retatrutide (LY3437943) with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Events Related to Study Drug. Started May 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04823208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823208.